 Kelly Knupp
Concepts (286)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anticonvulsants | 37 | 2026 | 242 | 7.500 |
Why?
| | Epilepsies, Myoclonic | 33 | 2026 | 59 | 7.410 |
Why?
| | Spasms, Infantile | 26 | 2025 | 136 | 7.200 |
Why?
| | Lennox Gastaut Syndrome | 8 | 2025 | 19 | 4.290 |
Why?
| | Epilepsy | 20 | 2026 | 387 | 3.390 |
Why?
| | Vigabatrin | 10 | 2025 | 19 | 2.700 |
Why?
| | Seizures | 29 | 2026 | 477 | 2.670 |
Why?
| | Adrenocorticotropic Hormone | 8 | 2025 | 147 | 2.520 |
Why?
| | Fenfluramine | 10 | 2025 | 17 | 2.160 |
Why?
| | Electroencephalography | 13 | 2026 | 551 | 1.800 |
Why?
| | Epilepsies, Partial | 5 | 2025 | 63 | 1.480 |
Why?
| | Drug Resistant Epilepsy | 8 | 2025 | 137 | 1.470 |
Why?
| | NAV1.1 Voltage-Gated Sodium Channel | 8 | 2026 | 22 | 1.110 |
Why?
| | Epilepsy, Generalized | 3 | 2023 | 20 | 1.090 |
Why?
| | Glucocorticoids | 3 | 2020 | 535 | 1.010 |
Why?
| | Caregivers | 7 | 2025 | 1049 | 0.960 |
Why?
| | Developmental Disabilities | 5 | 2025 | 281 | 0.950 |
Why?
| | Delphi Technique | 3 | 2024 | 331 | 0.950 |
Why?
| | Infant | 35 | 2026 | 10039 | 0.890 |
Why?
| | Plant Extracts | 4 | 2020 | 187 | 0.880 |
Why?
| | Child, Preschool | 35 | 2026 | 11799 | 0.870 |
Why?
| | Prednisolone | 5 | 2025 | 66 | 0.870 |
Why?
| | NAV1.6 Voltage-Gated Sodium Channel | 1 | 2024 | 11 | 0.850 |
Why?
| | Cannabidiol | 4 | 2022 | 136 | 0.840 |
Why?
| | Child | 50 | 2026 | 22657 | 0.800 |
Why?
| | Genetic Therapy | 2 | 2023 | 313 | 0.750 |
Why?
| | Status Epilepticus | 5 | 2024 | 67 | 0.750 |
Why?
| | Humans | 93 | 2026 | 144957 | 0.690 |
Why?
| | Medical Marijuana | 2 | 2019 | 123 | 0.650 |
Why?
| | Epilepsy, Absence | 3 | 2026 | 12 | 0.640 |
Why?
| | Dioxolanes | 2 | 2020 | 6 | 0.640 |
Why?
| | Sleep | 4 | 2024 | 901 | 0.620 |
Why?
| | Treatment Outcome | 21 | 2026 | 11695 | 0.600 |
Why?
| | Adolescent | 31 | 2026 | 22453 | 0.560 |
Why?
| | Male | 54 | 2026 | 72406 | 0.540 |
Why?
| | Leukomalacia, Periventricular | 1 | 2017 | 9 | 0.530 |
Why?
| | Thyrotropin | 1 | 2017 | 118 | 0.510 |
Why?
| | Practice Guidelines as Topic | 3 | 2026 | 1563 | 0.510 |
Why?
| | Precision Medicine | 1 | 2021 | 458 | 0.510 |
Why?
| | Female | 54 | 2026 | 78376 | 0.500 |
Why?
| | Infant, Premature, Diseases | 1 | 2017 | 111 | 0.470 |
Why?
| | Disease Progression | 4 | 2025 | 2852 | 0.460 |
Why?
| | Cannabis | 3 | 2020 | 509 | 0.460 |
Why?
| | Treatment Failure | 1 | 2016 | 365 | 0.450 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2017 | 319 | 0.450 |
Why?
| | Executive Function | 3 | 2025 | 461 | 0.440 |
Why?
| | Perception | 1 | 2017 | 377 | 0.420 |
Why?
| | Lafora Disease | 1 | 2014 | 1 | 0.420 |
Why?
| | Unverricht-Lundborg Syndrome | 1 | 2014 | 1 | 0.420 |
Why?
| | Prospective Studies | 15 | 2026 | 7997 | 0.410 |
Why?
| | Video Recording | 2 | 2026 | 213 | 0.410 |
Why?
| | Testosterone | 1 | 2017 | 419 | 0.400 |
Why?
| | Oligonucleotides, Antisense | 2 | 2026 | 116 | 0.400 |
Why?
| | Myoclonus | 2 | 2023 | 17 | 0.390 |
Why?
| | Migraine Disorders | 2 | 2024 | 112 | 0.390 |
Why?
| | Administration, Oral | 5 | 2019 | 848 | 0.390 |
Why?
| | Physicians | 1 | 2021 | 940 | 0.380 |
Why?
| | Adrenal Cortex Hormones | 1 | 2016 | 479 | 0.370 |
Why?
| | Epileptic Syndromes | 5 | 2024 | 96 | 0.340 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 384 | 0.330 |
Why?
| | Cost of Illness | 3 | 2018 | 321 | 0.330 |
Why?
| | Coronavirus Infections | 3 | 2020 | 378 | 0.330 |
Why?
| | Hypertension | 1 | 2019 | 1264 | 0.330 |
Why?
| | Parents | 3 | 2022 | 1403 | 0.320 |
Why?
| | Retrospective Studies | 14 | 2025 | 17101 | 0.310 |
Why?
| | Quality of Life | 6 | 2026 | 3192 | 0.290 |
Why?
| | Young Adult | 11 | 2026 | 14126 | 0.290 |
Why?
| | Pandemics | 4 | 2022 | 1695 | 0.280 |
Why?
| | Dronabinol | 3 | 2022 | 247 | 0.280 |
Why?
| | Cognition | 3 | 2025 | 1269 | 0.270 |
Why?
| | Cohort Studies | 8 | 2025 | 5965 | 0.270 |
Why?
| | Neuropsychological Tests | 4 | 2025 | 1137 | 0.270 |
Why?
| | Cannabinoids | 2 | 2022 | 182 | 0.260 |
Why?
| | Genetic Testing | 2 | 2023 | 482 | 0.260 |
Why?
| | Biological Ontologies | 1 | 2025 | 21 | 0.220 |
Why?
| | Smartphone | 1 | 2026 | 102 | 0.220 |
Why?
| | Headache | 1 | 2006 | 150 | 0.220 |
Why?
| | Diet, Ketogenic | 1 | 2025 | 38 | 0.220 |
Why?
| | Seizures, Febrile | 1 | 2024 | 23 | 0.220 |
Why?
| | Dichloroacetic Acid | 1 | 2024 | 7 | 0.220 |
Why?
| | Double-Blind Method | 4 | 2023 | 2029 | 0.220 |
Why?
| | Child Behavior Disorders | 1 | 2026 | 118 | 0.220 |
Why?
| | Delivery of Health Care | 3 | 2020 | 947 | 0.210 |
Why?
| | Vagus Nerve Stimulation | 1 | 2024 | 29 | 0.210 |
Why?
| | Problem Behavior | 1 | 2026 | 102 | 0.210 |
Why?
| | Adult | 13 | 2025 | 40506 | 0.210 |
Why?
| | Acidosis, Lactic | 1 | 2024 | 45 | 0.210 |
Why?
| | Analgesics | 1 | 2006 | 231 | 0.210 |
Why?
| | Natural Language Processing | 1 | 2025 | 103 | 0.200 |
Why?
| | Epilepsy, Reflex | 1 | 2023 | 2 | 0.200 |
Why?
| | Comorbidity | 2 | 2019 | 1660 | 0.200 |
Why?
| | Betacoronavirus | 3 | 2020 | 286 | 0.190 |
Why?
| | Lymphocytes | 1 | 2025 | 382 | 0.190 |
Why?
| | Family | 2 | 2018 | 679 | 0.190 |
Why?
| | Wakefulness | 1 | 2024 | 169 | 0.190 |
Why?
| | Spasm | 1 | 2022 | 21 | 0.180 |
Why?
| | Cosyntropin | 1 | 2022 | 7 | 0.180 |
Why?
| | Sodium Channel Blockers | 1 | 2021 | 24 | 0.170 |
Why?
| | Benzazepines | 2 | 2018 | 35 | 0.170 |
Why?
| | Outpatients | 1 | 2025 | 443 | 0.170 |
Why?
| | Delayed Diagnosis | 1 | 2021 | 95 | 0.170 |
Why?
| | Dependovirus | 1 | 2021 | 79 | 0.160 |
Why?
| | Shab Potassium Channels | 1 | 2020 | 20 | 0.160 |
Why?
| | KCNQ2 Potassium Channel | 1 | 2020 | 15 | 0.160 |
Why?
| | Follow-Up Studies | 5 | 2026 | 5417 | 0.160 |
Why?
| | Standard of Care | 1 | 2020 | 80 | 0.150 |
Why?
| | Internationality | 1 | 2020 | 156 | 0.150 |
Why?
| | Infant, Newborn | 7 | 2024 | 6434 | 0.150 |
Why?
| | Causality | 1 | 2019 | 126 | 0.150 |
Why?
| | Hormones | 1 | 2019 | 134 | 0.150 |
Why?
| | Machine Learning | 1 | 2025 | 587 | 0.150 |
Why?
| | Eyelids | 3 | 2023 | 41 | 0.140 |
Why?
| | Drug Approval | 1 | 2019 | 91 | 0.140 |
Why?
| | Mutation | 3 | 2023 | 4099 | 0.140 |
Why?
| | Health Surveys | 2 | 2018 | 518 | 0.140 |
Why?
| | Health Care Surveys | 1 | 2020 | 539 | 0.140 |
Why?
| | Tandem Mass Spectrometry | 2 | 2022 | 577 | 0.140 |
Why?
| | Phenobarbital | 1 | 2018 | 20 | 0.140 |
Why?
| | Mitochondria | 1 | 2025 | 984 | 0.140 |
Why?
| | Sickness Impact Profile | 1 | 2018 | 62 | 0.130 |
Why?
| | Animals | 6 | 2021 | 38109 | 0.130 |
Why?
| | Incidence | 2 | 2019 | 2883 | 0.130 |
Why?
| | Urine | 1 | 2017 | 62 | 0.130 |
Why?
| | Heterogeneous-Nuclear Ribonucleoprotein U | 1 | 2017 | 7 | 0.130 |
Why?
| | United States | 7 | 2019 | 15988 | 0.130 |
Why?
| | Body Height | 1 | 2017 | 202 | 0.120 |
Why?
| | Heterozygote | 1 | 2017 | 315 | 0.120 |
Why?
| | Brain | 3 | 2018 | 2941 | 0.120 |
Why?
| | Surveys and Questionnaires | 4 | 2021 | 6053 | 0.120 |
Why?
| | Employment | 1 | 2018 | 188 | 0.120 |
Why?
| | Neuroimaging | 1 | 2018 | 292 | 0.120 |
Why?
| | Plasma | 1 | 2017 | 225 | 0.120 |
Why?
| | Benzimidazoles | 1 | 2017 | 190 | 0.120 |
Why?
| | Intellectual Disability | 1 | 2017 | 175 | 0.110 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1268 | 0.110 |
Why?
| | Serotonin | 1 | 2017 | 294 | 0.110 |
Why?
| | Neurology | 3 | 2020 | 114 | 0.110 |
Why?
| | Health Care Costs | 1 | 2018 | 427 | 0.100 |
Why?
| | Nervous System Diseases | 1 | 2017 | 284 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 966 | 0.100 |
Why?
| | Telemedicine | 2 | 2020 | 948 | 0.100 |
Why?
| | Guideline Adherence | 1 | 2018 | 589 | 0.100 |
Why?
| | Neurosurgical Procedures | 1 | 2015 | 202 | 0.100 |
Why?
| | Body Weight | 1 | 2017 | 978 | 0.100 |
Why?
| | Infant, Premature | 1 | 2017 | 611 | 0.090 |
Why?
| | Colorado | 2 | 2019 | 4564 | 0.090 |
Why?
| | Pentobarbital | 1 | 2011 | 17 | 0.090 |
Why?
| | Age of Onset | 3 | 2018 | 551 | 0.090 |
Why?
| | Observational Studies as Topic | 2 | 2024 | 129 | 0.090 |
Why?
| | Communication | 3 | 2024 | 967 | 0.080 |
Why?
| | Consensus | 2 | 2023 | 489 | 0.080 |
Why?
| | Mental Health | 1 | 2018 | 792 | 0.080 |
Why?
| | Neurologists | 2 | 2021 | 22 | 0.080 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 886 | 0.080 |
Why?
| | Research Design | 1 | 2017 | 1137 | 0.080 |
Why?
| | Piracetam | 1 | 2010 | 14 | 0.080 |
Why?
| | Biomedical Research | 1 | 2017 | 710 | 0.080 |
Why?
| | Limit of Detection | 2 | 2022 | 97 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2021 | 2313 | 0.080 |
Why?
| | Hypnotics and Sedatives | 1 | 2011 | 216 | 0.080 |
Why?
| | Forecasting | 2 | 2024 | 391 | 0.070 |
Why?
| | Middle Aged | 7 | 2025 | 35928 | 0.070 |
Why?
| | Prevalence | 1 | 2016 | 2836 | 0.070 |
Why?
| | Health Resources | 2 | 2020 | 130 | 0.070 |
Why?
| | Hyperventilation | 1 | 2026 | 15 | 0.060 |
Why?
| | Post-Dural Puncture Headache | 1 | 2026 | 5 | 0.060 |
Why?
| | Injections, Spinal | 1 | 2026 | 121 | 0.060 |
Why?
| | Drug Therapy, Combination | 2 | 2020 | 1048 | 0.060 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2005 | 59 | 0.060 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2025 | 75 | 0.060 |
Why?
| | Pyruvate Dehydrogenase (Lipoamide) | 1 | 2024 | 10 | 0.050 |
Why?
| | Oxytocin | 1 | 2005 | 51 | 0.050 |
Why?
| | Cell Respiration | 1 | 2025 | 107 | 0.050 |
Why?
| | Europe | 1 | 2026 | 412 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2019 | 1540 | 0.050 |
Why?
| | Maternal Behavior | 1 | 2005 | 84 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2026 | 2032 | 0.050 |
Why?
| | Diagnosis, Differential | 2 | 2006 | 1495 | 0.050 |
Why?
| | Disease Management | 2 | 2020 | 647 | 0.050 |
Why?
| | Rare Diseases | 1 | 2025 | 113 | 0.050 |
Why?
| | Hyalin | 1 | 2004 | 3 | 0.050 |
Why?
| | Heredodegenerative Disorders, Nervous System | 1 | 2004 | 3 | 0.050 |
Why?
| | Intranuclear Inclusion Bodies | 1 | 2004 | 4 | 0.050 |
Why?
| | Wechsler Scales | 1 | 2024 | 59 | 0.050 |
Why?
| | Syncope | 1 | 2024 | 55 | 0.050 |
Why?
| | Aggression | 1 | 2005 | 179 | 0.050 |
Why?
| | Introns | 1 | 2024 | 254 | 0.050 |
Why?
| | Social Behavior | 1 | 2026 | 288 | 0.050 |
Why?
| | Signal Transduction | 1 | 2017 | 5233 | 0.050 |
Why?
| | Phenotype | 2 | 2025 | 3164 | 0.050 |
Why?
| | Mutation, Missense | 1 | 2025 | 340 | 0.050 |
Why?
| | Up-Regulation | 1 | 2026 | 852 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2015 | 2920 | 0.050 |
Why?
| | Rectum | 1 | 2004 | 180 | 0.050 |
Why?
| | Fatty Acids | 1 | 2025 | 452 | 0.040 |
Why?
| | Oxygen Consumption | 1 | 2025 | 724 | 0.040 |
Why?
| | Pediatrics | 2 | 2020 | 1115 | 0.040 |
Why?
| | Risk Factors | 1 | 2016 | 10792 | 0.040 |
Why?
| | Eosinophils | 1 | 2004 | 316 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 3 | 2020 | 3869 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2026 | 1990 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2024 | 901 | 0.040 |
Why?
| | Inpatients | 1 | 2025 | 546 | 0.040 |
Why?
| | Health Services | 1 | 2021 | 115 | 0.040 |
Why?
| | Emotions | 1 | 2026 | 578 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2022 | 454 | 0.040 |
Why?
| | Videoconferencing | 1 | 2020 | 66 | 0.040 |
Why?
| | Tuberous Sclerosis | 1 | 2020 | 56 | 0.040 |
Why?
| | Adaptation, Psychological | 1 | 2025 | 717 | 0.040 |
Why?
| | Placebos | 1 | 2019 | 193 | 0.040 |
Why?
| | Internet | 1 | 2024 | 700 | 0.040 |
Why?
| | Cell Line | 1 | 2025 | 2882 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2019 | 115 | 0.040 |
Why?
| | Half-Life | 1 | 2019 | 151 | 0.040 |
Why?
| | Pilot Projects | 1 | 2025 | 1890 | 0.040 |
Why?
| | Pediatricians | 1 | 2020 | 121 | 0.040 |
Why?
| | Biological Availability | 1 | 2019 | 142 | 0.040 |
Why?
| | Energy Metabolism | 1 | 2025 | 936 | 0.040 |
Why?
| | Drug Resistance | 1 | 2019 | 153 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2019 | 334 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2020 | 5872 | 0.040 |
Why?
| | Gene Ontology | 1 | 2018 | 54 | 0.030 |
Why?
| | Neurologic Examination | 2 | 2011 | 131 | 0.030 |
Why?
| | Preexisting Condition Coverage | 1 | 2017 | 2 | 0.030 |
Why?
| | Critical Illness | 1 | 2024 | 892 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2947 | 0.030 |
Why?
| | Intestinal Mucosa | 1 | 2004 | 676 | 0.030 |
Why?
| | Atmospheric Pressure | 1 | 2017 | 26 | 0.030 |
Why?
| | Proteomics | 1 | 2024 | 1195 | 0.030 |
Why?
| | Waiting Lists | 1 | 2019 | 263 | 0.030 |
Why?
| | Agenesis of Corpus Callosum | 1 | 2017 | 13 | 0.030 |
Why?
| | Ribonucleoproteins, Small Nuclear | 1 | 2017 | 22 | 0.030 |
Why?
| | Efficiency | 1 | 2018 | 104 | 0.030 |
Why?
| | Muscle Hypotonia | 1 | 2017 | 33 | 0.030 |
Why?
| | Qualitative Research | 1 | 2025 | 1671 | 0.030 |
Why?
| | Receptors, Serotonin | 1 | 2017 | 35 | 0.030 |
Why?
| | Medicaid | 1 | 2021 | 462 | 0.030 |
Why?
| | Global Health | 1 | 2020 | 401 | 0.030 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2017 | 79 | 0.030 |
Why?
| | Chromosome Deletion | 1 | 2017 | 124 | 0.030 |
Why?
| | Income | 1 | 2018 | 202 | 0.030 |
Why?
| | Drug Costs | 1 | 2018 | 116 | 0.030 |
Why?
| | Microcephaly | 1 | 2017 | 103 | 0.030 |
Why?
| | Animals, Genetically Modified | 1 | 2017 | 250 | 0.030 |
Why?
| | Larva | 1 | 2017 | 242 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2018 | 285 | 0.030 |
Why?
| | RNA Splicing | 1 | 2017 | 285 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2017 | 598 | 0.030 |
Why?
| | Central Nervous System | 1 | 2017 | 281 | 0.030 |
Why?
| | Gestational Age | 1 | 2018 | 975 | 0.030 |
Why?
| | Vaccination | 1 | 2022 | 1423 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 343 | 0.020 |
Why?
| | Zebrafish | 1 | 2017 | 528 | 0.020 |
Why?
| | Genetic Variation | 1 | 2017 | 984 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2017 | 906 | 0.020 |
Why?
| | Sex Factors | 1 | 2017 | 2114 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2011 | 423 | 0.020 |
Why?
| | Protein Binding | 1 | 2017 | 2276 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4293 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2010 | 200 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 783 | 0.020 |
Why?
| | Kidney | 1 | 2017 | 1496 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2017 | 2365 | 0.020 |
Why?
| | Depression | 1 | 2018 | 1559 | 0.020 |
Why?
| | Obesity | 1 | 2021 | 3082 | 0.020 |
Why?
| | Hospitalization | 1 | 2018 | 2434 | 0.020 |
Why?
| | Acute Disease | 1 | 2010 | 1031 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2017 | 4569 | 0.010 |
Why?
| | Nalidixic Acid | 1 | 2005 | 1 | 0.010 |
Why?
| | Naphthyridines | 1 | 2005 | 20 | 0.010 |
Why?
| | Fluoxetine | 1 | 2005 | 54 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 2738 | 0.010 |
Why?
| | Drug Synergism | 1 | 2005 | 357 | 0.010 |
Why?
| | Submucous Plexus | 1 | 2004 | 2 | 0.010 |
Why?
| | Myenteric Plexus | 1 | 2004 | 4 | 0.010 |
Why?
| | Consanguinity | 1 | 2004 | 49 | 0.010 |
Why?
| | Postpartum Period | 1 | 2005 | 365 | 0.010 |
Why?
| | Aged | 1 | 2022 | 25947 | 0.010 |
Why?
| | Behavior, Animal | 1 | 2005 | 520 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 1077 | 0.010 |
Why?
| | Ultrasonography | 1 | 2004 | 770 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2005 | 2540 | 0.010 |
Why?
| | Time Factors | 1 | 2010 | 7183 | 0.010 |
Why?
| | Rats | 1 | 2005 | 5614 | 0.010 |
Why?
| | Neurons | 1 | 2004 | 1642 | 0.010 |
Why?
| | Pregnancy | 1 | 2005 | 7191 | 0.010 |
Why?
|
|
Knupp's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|